I started practicing medical weight loss in Coastal Georgia in 2005, six years after completing my training and establishing what would become Scale Solutions. By that point, I had already watched enough patients struggle — and enough “solutions” come and go — to have shed most of my optimism about the field’s near-term prospects. That may sound bleak for an opening, but it sets up the honest version of what the past two decades have actually looked like: long stretches of modest tools, real but limited results, and the kind of incremental progress that rarely makes headlines. And then, starting around 2020, something genuinely different arrived.
This is an account of what I have seen practicing medical weight loss in Savannah and the surrounding region across those years — not a clinical review, not a guide to a specific treatment, but a physician’s honest accounting of a field in transformation. It is written for patients who have lived through some of the same chapters from the other side of the exam table, and for anyone trying to understand how we arrived at the remarkable moment we are in now.
I have seen a lot of patients over twenty years. I have seen real change in people’s lives and I have seen real harm done — mostly by the unregulated and the unmonitored. What follows is my attempt to tell that story plainly.
Part One: The Phentermine Era (2005–2010)
When I opened my practice in Savannah, the pharmacological toolkit for medical weight management was genuinely thin. The options available to a physician who wanted to help a patient lose weight with medication were, for the most part: phentermine, phentermine, and phentermine.
Phentermine is a sympathomimetic amine — a stimulant that suppresses appetite by acting on the central nervous system. It had been in clinical use since the 1950s and received FDA approval for short-term use in obesity in 1959. In 1997, the fen-phen debacle — in which the combination of fenfluramine and phentermine was linked to valvular heart disease — removed fenfluramine from the market and cast a long shadow over the entire class. What remained was phentermine alone, approved for short-term use only, generating some suspicion even among patients and physicians who recognized that it actually worked reasonably well for what it was.
And it did work, in a limited way. Patients on phentermine with appropriate dietary guidance typically lost 5 to 10 percent of body weight over the approved short treatment duration. The problem was that “short-term” was not a solution for a chronic condition. When patients stopped — as the label required — the weight came back. This was not failure of character or failure of the medication; it was failure of the treatment framework. Obesity is not a short-term problem, and treating it with a short-term drug produced short-term results.
The other option available in those years was orlistat, an intestinal lipase inhibitor that prevented absorption of some dietary fat. It was modestly effective — producing about 3 to 5 percent weight loss above placebo in trials — and practically limited by gastrointestinal side effects that many patients found unacceptable. I prescribed it when appropriate and found it useful for a carefully selected subset of patients, but it was not a population-level solution.
What worked consistently in those early years was structure: a physician who saw patients regularly, who measured and documented and adjusted, who treated weight as a medical problem and not a personal deficiency. The tools were limited. The clinical framework mattered. I learned that lesson early and built Scale Solutions around it.
Part Two: The HCG and “Everyone’s a Clinic” Middle Years (2010–2015)
The second chapter of my practice was dominated not by what medicine did but by what happened outside of medicine. Between 2010 and 2015, the weight loss industry in Savannah — as in cities across the South — underwent a kind of proliferation. Weight loss clinics appeared in strip malls, in medical office parks, in places that had previously been other things entirely. Some were physician-led and well-run. Many were not.
The product at the center of this moment was HCG — human chorionic gonadotropin, a hormone produced during pregnancy — marketed as a weight loss treatment in combination with a severely calorie-restricted diet of 500 calories per day. The FDA had warned since 1976 that HCG had no proven effect on weight loss and that the weight loss observed in HCG programs was attributable to the severe caloric restriction alone. The agency issued updated warnings in 2011 and took action against numerous manufacturers of over-the-counter HCG products. None of this stopped the proliferation of HCG programs during this period.
What the data showed — what any rigorous review of the evidence showed — was exactly what the FDA had stated for decades: HCG produced no weight loss beyond that achieved by the same severe caloric restriction without the hormone. The weight that patients lost was real, though often unsustainable at 500 calories per day for any extended period. The HCG itself was a placebo that came with a real risk: the 500-calorie diet, particularly when pursued without medical supervision, caused muscle loss, nutritional deficiencies, and in some cases more serious complications. Patients who stopped these programs almost universally regained what they had lost.
I want to be careful here about generalizing unfairly. There were legitimate physicians running legitimate programs during this period who provided real value to patients. The problem was that the environment made it difficult for patients to distinguish between them. When a physician-led practice and a poorly supervised strip-mall clinic both advertise “medical weight loss,” the label provides no meaningful protection.
This era reinforced for me that the physician-led distinction is not a marketing claim — it is a clinical standard with real consequences for patient safety. I have written more about our approach to this at scale-solutions.com/about-dr-gates/.
Part Three: The Lipotropic, B12, and Compounding Era (2015–2020)
By the middle of the decade, legitimate weight loss medicine had modestly expanded its toolkit. Two new FDA-approved medications — lorcaserin (Belviq) and the combination of phentermine/topiramate (Qsymia), along with naltrexone/bupropion (Contrave) — entered the market between 2012 and 2014. Each produced more meaningful weight loss than the previous generation, and each was designed for longer-term use rather than the short-term framework of phentermine alone. These were genuine clinical advances, though their uptake was limited by cost, insurance coverage gaps, and in the case of lorcaserin, eventual market withdrawal in 2020 due to a potential cancer signal in post-marketing surveillance.
This period also brought liraglutide (Saxenda), the first GLP-1 receptor agonist approved specifically for obesity management, in 2014. At the time, it represented a conceptual shift as much as a pharmacological one: treating obesity through the hormonal systems that govern appetite rather than through stimulant suppression or mechanical fat malabsorption. The results were real — about 8 percent mean weight loss in the pivotal trial — and for a meaningful subset of patients, substantially better than that. The daily injection requirement limited uptake, and the cost was formidable for the majority of patients without strong coverage. But the direction was right.
The compounding pharmacy ecosystem expanded significantly during these years. Lipotropic injections — combinations of methionine, inositol, choline, and B12, often called MIC shots — became a standard offering at many weight loss clinics, Scale Solutions included. The evidence base for lipotropic injections as independent drivers of weight loss is modest; their primary value is in supporting metabolic function and energy levels during caloric restriction, rather than producing direct fat loss through any demonstrated mechanism. I have always been transparent with my patients about what these injections do and do not do. They are a supportive tool, not a primary treatment, and the distinction matters.
B12 injections — also widely offered — have a clear role in patients with documented B12 deficiency or absorption issues, a common finding in older adults and in patients on metformin. Their value in patients with normal B12 levels as a weight loss strategy is less clearly established by the evidence. Nonetheless, many patients report improved energy with B12 supplementation, and the safety profile is excellent. We continue to offer these as part of a comprehensive program. More detail on our current approach is at scale-solutions.com/b12-lipotropic-shots/ and scale-solutions.com/super-lipotropic-injections/.
The honest assessment of the 2015–2020 period is this: meaningful progress was made, but it was incremental. We were doing better medicine than in 2005, but the fundamental challenge of obesity as a chronic disease requiring long-term treatment remained only partially addressed. Something more was needed.
Part Four: GLP-1s Change Everything (2020–2025)
I remember reading the STEP-1 trial results when they were published in the New England Journal of Medicine in 2021 and feeling something I rarely allow myself in clinical practice: genuine surprise. A mean weight loss of approximately 15 percent of body weight at 68 weeks in adults without diabetes. Not 5 percent, not 8 percent — numbers I had calibrated my clinical expectations around for two decades — but 15 percent. And not from a surgical procedure, not from a combination of risky stimulants, but from a once-weekly subcutaneous injection of a hormone-mimicking molecule that the gut produces naturally.
The SURMOUNT-1 trial results for tirzepatide, published in 2022, pushed the expectation higher still — approximately 20 to 22 percent mean weight loss at the highest dose. For context: bariatric surgery had long been the reference standard for durable, significant weight loss, with sleeve gastrectomy producing roughly 25 to 30 percent excess weight loss. The gap between pharmacological and surgical outcomes was closing in a way that would have been dismissed as unrealistic at any point in my prior career.
For patients in Savannah and across Coastal Georgia, the practical reality of this moment was complicated. Ozempic — the diabetes formulation of semaglutide — became a household name in a way that few drugs in my lifetime have. Demand far outpaced supply. Compounding pharmacies began producing semaglutide and tirzepatide at scale to fill the gap, operating in a gray area of FDA enforcement that would eventually be addressed but that, in 2022 and 2023, created a parallel market that was largely unregulated and variable in quality.
I navigated this period carefully. Compounded medications existed on a spectrum: some were produced by responsible, FDA-registered 503B facilities with appropriate quality controls; others were of genuinely uncertain provenance. I made decisions on a case-by-case basis, prioritized brand products when accessible, and was transparent with patients about what was and was not known. The FDA’s enforcement actions in 2024 and 2025 — declaring the shortage resolved and restricting compounded production — brought clarity that had been lacking, though it also created access challenges for patients who had been stable on lower-cost compounded options.
The cardiovascular data added another dimension. The SELECT trial, published in the New England Journal of Medicine in 2023, demonstrated that semaglutide significantly reduced major adverse cardiovascular events — heart attacks, strokes, cardiovascular death — in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. This was not merely a weight loss drug; it was a cardiovascular risk reduction therapy. The clinical implications for my patient population — many of whom carry the cardiovascular comorbidity burden that comes with Coastal Georgia’s broader metabolic health challenges — are profound.
If you want to understand where we are with semaglutide and tirzepatide specifically, I have written clinical summaries at scale-solutions.com/semaglutide/ and scale-solutions.com/tirzepatide/.
Part Five: Where We Are Now (2026)
As of this writing in 2026, the GLP-1 landscape is more mature than it was three years ago but still actively evolving. Brand products are more reliably available than during the peak shortage. The compounding rollback, while disruptive for some patients, has produced a cleaner regulatory environment for those of us who preferred not to operate in regulatory ambiguity. New medications are in the pipeline — orforglipron, an oral non-peptide GLP-1 agent without the administration restrictions of oral semaglutide, has completed Phase 3 trials and may be approved by the time you read this. CagriSema, a combination of semaglutide and the amylin analogue cagrilintide, has shown trial results in the 22 to 25 percent weight loss range.
The Medicare landscape is changing for the first time in a generation. The Bridge program — designed to provide Medicare Part D beneficiaries access to GLP-1 medications for obesity at approximately $50 per month — represents a policy shift that would have seemed politically impossible five years ago. It is not yet fully implemented, and plan participation is rolling out. But the direction is set. More information on this is at scale-solutions.com/medicare-glp-1-bridge-georgia/.
The commercial insurance landscape remains complicated. BCBS Georgia, Humana, Aetna, Cigna, and UnitedHealthcare all have prior authorization requirements that can be navigated but require a physician’s active involvement. Scale Solutions manages this process for our patients — the prior authorization paperwork, the peer-to-peer calls with insurance medical directors, the appeals when needed. It is not glamorous work, but it is essential to actually getting people treated.
The question I get asked most often by new patients is some version of: “Is this different?” They have lost and regained. They have tried programs and supplements and interventions of varying credibility. They are asking whether GLP-1 therapy is genuinely different from what came before, or whether it is the next thing in a long line of things that work for a while and then don’t.
My honest answer is: yes, it is different — and the evidence supports that conclusion in ways I did not expect to see in my career. It is different in the magnitude of weight loss, in the durability of results during treatment, in the cardiovascular and metabolic benefits that extend beyond the scale. It is not a cure — the STEP-4 data on weight regain after discontinuation makes that clear, and I discuss this plainly with every patient. It is a treatment for a chronic disease that requires ongoing management, like treatment for hypertension or hypothyroidism. That framing is important for setting realistic expectations and building the durable habits that determine what happens in the long run. More on what the evidence says about stopping is at scale-solutions.com/what-happens-if-you-stop-glp-1/, and a comprehensive overview of the GLP-1 class is at scale-solutions.com/glp-1-weight-loss/.
What Hasn’t Changed
After twenty years, the most important thing I can tell you is also the simplest: the tools have changed, dramatically and for the better. What hasn’t changed is what the tools are for.
A GLP-1 prescription without a physician who knows you, who has reviewed your medications and your history, who can recognize when your side effect pattern is routine and when it is something that needs immediate attention — that is a prescription without a foundation. I have watched the telehealth-first, form-and-mail-a-prescription model expand rapidly in this space, and I have seen patients arrive at our offices with complications, questions, and concerns that were never addressed. The convenience is real. The clinical gaps are also real.
What Scale Solutions has always provided — through the phentermine era, through the HCG chaos, through the compounding gray market, and into the GLP-1 transformation — is a physician who knows the patient’s name, who has read their chart, who shows up. That is not a small thing. In a field that has historically attracted a great deal of opportunism, it is the thing that actually matters most.
I am proud of what we have built in Coastal Georgia over these years. I am proud of the patients who trusted us with their care across that time. And for the first time in my career, I am genuinely optimistic about what the next decade looks like — not because the tools are finally perfect, but because they are, for the first time, actually adequate to the size of the problem.
If you are considering starting this conversation with us, I hope to see you at one of our three offices — in Savannah, Pooler, or Hinesville. If you are an existing patient, thank you for the years.
— Dr. Donald L. Gates, MD
Scale Solutions | scale-solutions.com | (912) 352-7546
Disclaimer: This op-ed represents the professional perspective and clinical observations of Dr. Donald L. Gates, MD and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified physician. References to specific medications reflect general medical knowledge and do not constitute an endorsement of any specific product or manufacturer. Clinical trial data cited reflects published literature as of the writing date; consult current sources for the most recent evidence. Last reviewed: June 2026.